Aris Angelis (A Angelis)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 12

Top Venues

Nature medicine

Journal of the Royal Society of Medicine

British journal of clinical pharmacology

Applied health economics and health policy

London School of Economics and Political Science (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

London School of Economics and Political Science Oct 01 2012 - Sep 30 2016

United Kingdom

PHD

London School of Economics and Political Science Sep 01 2008 - Aug 31 2009

United Kingdom

MSC

King's College London Sep 01 2007 - Aug 31 2008

United Kingdom

MSC

Imperial College London Sep 01 2004 - Aug 31 2007

United Kingdom

BSC

Publications

Aris Angelis, Ajay Aggarwal, Andrew H Briggs
The success of NHS England's Innovative Medicines Fund will depend on its operational details. Nature medicine 29 (2) (2023)
Aris Angelis, Ajay Aggarwal, Andrew H Briggs
The success of NHS England's Innovative Medicines Fund will depend on its operational details. Nature medicine (2023)
Aris Angelis, Ajay Aggarwal, Alec Miners, Richard Grieve, John Cairns, Andrew Briggs
The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep? Journal of the Royal Society of Medicine (2023)
Aris Angelis, Ajay Aggarwal, Andrew H Briggs
The success of NHS England's Innovative Medicines Fund will depend on its operational details. Nature medicine 29 (2) (2023)
Aris Angelis, Ajay Aggarwal, Andrew H Briggs
The success of NHS England's Innovative Medicines Fund will depend on its operational details. Nature medicine 29 (2) (2023)
Aris Angelis, J E Mellerio, P Kanavos
Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study. Orphanet journal of rare diseases 17 (1) (2022)
Aris Angelis, Huseyin Naci, Allan Hackshaw
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies. PharmacoEconomics 38 (12) (2021)
Aris Angelis, Mark Thursz, Vlad Ratziu, Alastair O'Brien, Lawrence Serfaty, Ali Canbay, Ingolf Schiefke, Joao Bana E Costa, Pascal Lecomte, Panos Kanavos
Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. Medical decision making : an international journal of the Society for Medical Decision Making 40 (6) (2021)
Aris Angelis, Lawrence D Phillips
Advancing structured decision-making in drug regulation at the FDA and EMA. British journal of clinical pharmacology 87 (2) (2020)
Aris Angelis, Panos Kanavos
Comment on: "Does MCDA Trump CEA?" Applied health economics and health policy 17 (1) (2019)
Aris Angelis
Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden. MDM policy & practice 3 (2) (2018)
Aris Angelis, Gilberto Montibeller, Daniel Hochhauser, Panos Kanavos
Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC medical informatics and decision making 17 (1) (2017)

Aris Angelis.css-eqlu8i{font-size:small;padding-left:4px;} (A Angelis)

Publication Activity (10 Years)

Top Topics

Top Venues

Aris Angelis (A Angelis)